GlassScriptPhysician profile
Martha Berry
NPI 1073569828
$912.75
in general payments reported to CMS, 2019-2025
18 companies · $292 in 2025
The $292 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.05 · 2023: $300 · 2024: $306 · 2025: $292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $899.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $898.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $256.60 | 2023-2025 | |
| Novo Nordisk INC | $110.56 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $87.83 | 2023-2025 | Veozah |
| Lilly USA, LLC | $59.58 | 2021-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $58.27 | 2024-2025 | Farxiga, Airsupra |
| Sumitomo Pharma America, INC. | $48.11 | 2024-2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $43.06 | 2023-2025 | |
| Antares Pharma, INC. | $38.01 | 2023-2024 | Xyosted, Nocdurna, Tlando |
| Phathom Pharmaceuticals, INC. | $37.65 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $37.42 | 2025 | Gardasil 9, Capvaxive |
| Sanofi-Aventis U.S. LLC | $20.84 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.38 | 2024 | Ofev |
| Novartis Pharmaceuticals Corporation | $18.97 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.27 | 2024 | Xifaxan, Trulance |
| Pfizer INC. | $16.34 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $15.90 | 2024 | Trelegy Ellipta, Arexvy |
| Janssen Pharmaceuticals, INC | $13.62 | 2023 | Xarelto |
| Idorsia Pharmaceuticals US INC | $13.34 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martha Berry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.